Last Updated : December 7, 2015
Details
FilesGeneric Name:
Alirocumab
Project Status:
Complete
Therapeutic Area:
Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia
Manufacturer:
Sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Praluent
Project Line:
Reimbursement Review
Project Number:
SR0469-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Submission Type:
Initial
Indications:
Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Files
Last Updated : December 7, 2015